Tareno Healthcare Funds Monthly Report, October 2026
Market review
The healthcare sector rose 9.9% in October, significantly outperforming global equities, which fell 0.8%. The strong rally also put the sector back in the lead year-to-date: With a gain of 15.6%, it outperformed the MSCI World (+10.9%). This performance was supported by a pronounced rotation away from AI and technology stocks. Investors increasingly viewed healthcare as a potential beneficiary of both political developments and the adoption of AI. Renewed discussions about expanding government-funded healthcare bolstered sentiment ahead of the U.S. elections. Growing awareness of AI-driven productivity gains, particularly in drug development and diagnostics, further enhanced the sector’s long-term appeal. Q3 earnings also supported stock prices. So far, 50% of the index companies have reported; 71% exceeded revenue expectations and 83% beat EPS estimates. The magnitude of the earnings surprises was largely in line with that of the second quarter. The results confirmed existing trends: Higher biopharma spending benefited Life Sciences Tools & Services. Lower utilization rates for more complex procedures weighed on MedTech and hospitals but benefited managed-care insurers thanks to better-than-expected medical loss ratios. On the M&A front, there were several transactions exceeding USD 1 billion, including the acquisition of Option Care by private-equity investors and McKesson for USD 5.8 billion, the acquisition of Surgery Partners by HealthSpan for USD 5.7 billion, the acquisition of Pacira Biosciences by Viatris for USD 1.7 billion, and the acquisition of Silence Therapeutics by Merck KGaA for USD 1.3 billion.
The pharmaceutical sector rose 11.4% and was among the main beneficiaries of the rotation from AI and technology stocks into more defensive sectors. Strong Q3 results from major pharmaceutical companies provided additional support for the sector’s performance. Clinical updates from the European Society for Medical Oncology (ESMO) conference also influenced stock prices, though reactions within the sector were mixed.
Providers & Services rose by 10.4%. Drug distributors (+13.6%) benefited from the flight to defensive stocks. McKesson and Cardinal Health received an additional boost from the extension of their drug distribution contracts with CVS through 2032. Managed care rose by 10.2%, supported by more favorable trends in treatment costs and expectations of a more favorable healthcare policy environment following the U.S. midterm elections. Medicare Advantage star ratings also influenced performance, with Humana emerging as the clear winner. Facilities rose 9.4% despite lower utilization for more complex procedures, as valuations benefited from expected policy changes following the U.S. elections. Services rose 8.4%, led by high single-digit to double-digit price gains in lab stocks.
Biotech (+9.9%) performed similarly to the pharmaceutical sector. Large companies benefited from defensive investor positioning, solid Q3 results, and clinical updates surrounding ESMO 2026. Highlights included encouraging data on Genmab’s petosemtamab in combination with Keytruda for head and neck cancer, as well as on Amgen’s imdelltra as a first-line maintenance therapy for small-cell lung cancer.
MedTech (+7.6%) rebounded in October despite ongoing weakness among orthopedic companies and disappointing Q3 results from several industry leaders. Nevertheless, numerous large-cap stocks rose from their lows following the quarterly earnings reports. Investors increasingly viewed earnings forecasts as less risky and considered valuations attractive relative to the broader healthcare sector. The markets for dental products and hearing aids presented a mixed picture, while fundamentals remained intact. Hospital equipment suppliers performed well and signaled solid investment demand.
Life Sciences Tools & Services rose 4.1% in October and took a breather following the strong rally of the previous months. Q3 results remained encouraging: Danaher and Thermo Fisher reported robust biopharma demand and stable spending in the Academia & Government segment. Positive results from CROs also bolstered confidence in a broad-based industry recovery. On the last trading day of October, however, the subsector lost 3%, weighed down by Illumina’s quarterly report, which failed to meet high investor expectations.
Tareno Sustainable Healthcare Fund Review
Last month, we neither established new positions nor closed existing ones. In October, the fund posted a return of 8.3%, while the benchmark index rose 9.9%.
The largest positive drivers of attribution relative to the index were:
- Genmab ( +42 bps): The stock rose 67% in October, buoyed by positive Phase 3 results for petosemtamab in head and neck cancer, Rina‑S in ovarian cancer, and epcoritamab in lymphomas.
- Roche ( +13 bps): The stock benefited from the strength of the pharmaceutical sector, solid Q3 results, and positive pipeline data on CT-996 (an oral GLP‑1 agonist), Sefaxersen, and Divarasib (presented at ESMO).
- Illumina ( +12 bps): Not invested.
The largest negative drivers of attribution relative to the index were:
- Eli Lilly ( -42 bps): The stock rose 23% in October. We are underweight relative to the index.
- Alnylam ( -32 bps): The stock declined following its Q3 results. Restrictions on insurance coverage, delays in the pipeline, and expectations that TTR’s annual revenue would be at the lower end of the forecast weighed on sentiment.
- Dexcom ( -28 bps): Concerns about CGM market growth following weaker-than-expected results from competitor Abbott weighed on the stock. Solid Q3 results and positive clinical data from the CONNECT study partially offset the weakness.
Tareno Impact Healthcare Fund Review
Last month, we neither established new positions nor closed any existing ones. In October, the fund generated a return of 6.1%.
The largest positive contributors were:
- Eli Lilly ( +76 bps): The overall strength of the pharmaceutical sector, regulatory progress (a positive recommendation from the EU CHMP for Foundayo), and better-than-expected Q3 results drove the stock higher.
- Teladoc ( +73 bps): Strong Q3 results.
- Sandoz ( +61 bps): The stock rose in the wake of the Capital Markets Day and continued its upward trend afterward. The Q3 revenue figures released on October 28 were mixed. Overall, the stock gained 16% in October.
The largest negative contributors were:
- Axsome (-69 bps): No specific news. Mixed signals regarding the progress of Auvelity’s (ADA) U.S. market launch, as well as several downward revisions to broker estimates ahead of the quarterly earnings report.
- Hypera (-61 bps): No company-specific news. The stock fell sharply amid a broad sell-off on the Brazilian stock market following President Lula’s reelection. Concerns about the fiscal outlook triggered a sharp revaluation of domestic stocks.
- BioNTech (-21 bps): Disappointing Phase 2/3 results for BNT113 in head and neck cancer. The primary endpoint for progression-free survival was not met.
Subscribe to the Healthcare Newsletter
Sign up for our newsletter and receive regular updates on the Tareno Healthcare Funds directly via email. Benefit from the fund management team’s insights on market developments, industry trends, and the positioning of the two healthcare strategies.
Publications
Tareno Healthcare Funds
Disclaimer
This document has been prepared for marketing and informational purposes and does not constitute an offer or a solicitation to subscribe to, buy, or sell shares of this investment fund. It does not constitute investment advice. Only the current fund documents (in particular, the prospectus and KID) are exclusively authoritative. Past performance is not a reliable indicator of future results.
Images: Marijke Vosmeer, Luzia Hunziker, Jürg Kaufmann, Istock, Unsplash / Graphics: Tareno AG / Bloomberg